Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLO: Delayed Radiotherapy in 1p/19q Codeleted Low-grade Oligodendrogliomas
NCT04702581Phase 3Recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- Dec 2021
- Primary completion
- Dec 2030
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of phenoxymethylpenicillin in Oligodendroglioma (OG) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Survival without neurocognitive deterioration at 9 years. Started Dec 2021; status: recruiting.
02
Drugs
phenoxymethylpenicillin
03
Conditions
Oligodendroglioma (OG)
Beyond the preview
Go deeper on NCT04702581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04702581.